Elotuzumab, Selinexor, and Dexamethasone (ESd)
IST-342
Phase 2 small_molecule terminated
Quick answer
Elotuzumab, Selinexor, and Dexamethasone (ESd) for Relapsed Multiple Myeloma is a Phase 2 program (small_molecule) at Karyopharm Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Karyopharm Therapeutics
- Indication
- Relapsed Multiple Myeloma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- terminated